TABLE 1.

Pertussis vaccines, vaccination schedules, and incidences in the five countries studied

Country	Vaccine	Manufacturer	Start of vaccination (yr)	% Coverage	Vaccination schedule	Incidence/100,000a	Protein variant expressed in vaccine
							Vaccine strain	PtxAf	Prn	FHA	Fim	TcfA
Finland	WCVb	KTLc	1952	96	3, 4, 5, 24 mo	6-18	1772	PtxA2	Prn1	NDh	Fim2,3	ND
							18530	PtxA4	Prn1	ND	Fim3	ND
Swedend	ACV	Glaxo-SmithKline	1996	∼100%	3, 5, 12 mo	11-31	Tohama	PtxA2	Prn1	ND	NPg	NP
	ACV	Aventis-Pasteur MSD	1997	∼100%	3, 5, 12 mo	11-31		ND	NP	ND	NP	NP
Germany (FRG)	WCV	Behringwerke	1955-1998	variable	3, 4, 5, 12-15 mo			ND	ND	ND	ND	ND
Germany (GDR)	WCV	State Institute	1964-1989	>95				ND	ND	ND	ND	ND
Germany	ACV	Glaxo-SmithKline	1995	>95	3, 4, 5, 11-14 mo, 9-17 yr, health care personnel	6-20	Tohama	PtxA2	Prn1	ND	NP	NP
		Aventis-Pasteur MSD	1995	>95	3, 4, 5, 11-14 mo, 9-17 yr, health care personnel	6-20		ND	NP	ND	NP	NP
		Chiron-Behring	1995	>95	3, 4, 5, 11-14 mo, 9-17 yr, health care professional	6-20		ND	ND	ND	NP	NP
The Netherlands	WCV	NVIe	1953	96	3, 4, 5, 11 mo	14-44	134	PtxA2	Prn1	FhaB1	Fim3	TcfA2
							509	PtxA4	Prn7	FhaB2	Fim2 or Fim2,3	TcfA2
France	WCV	Aventis-Pasteur MSD	1959	>90	2, 3, 4, 16-18 mo (until 1998)		IM1414	PtxA4	Prn1	ND	Fim 2 + 3	ND
							IM1416	PtxA2	Prn1	ND	Fim2	ND
	ACV	Glaxo-SmithKline	1998		16-18 mo, 11-13 yr		Tohama	PtxA2	Prn1	ND	NP	NP
		Aventis-Pasteur MSD	1998		16-18 mo, 11-13 yr			ND	NP	ND	NP	NP

^aCare should be taken when comparing incidences between countries, because of the different surveillance and diagnostic methods used.

^bVaccine contains equal amounts of the two strains.

^cNational Public Health Institute, Helsinki, Finland.

^dIn the Northern part of Sweden mainly a three-component ACV is used; in the southern part, a two-component ACV is used.

^eNetherlands Vaccine Institute, Bilthoven, The Netherlands.

^fPtxA, pertussis toxin S1 subunit.

^gNP, not present.

^hND, not determined.